Literature DB >> 20300058

Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices.

Charles E Rupprecht1, Deborah Briggs, Catherine M Brown, Richard Franka, Samuel L Katz, Harry D Kerr, Susan M Lett, Robin Levis, Martin I Meltzer, William Schaffner, Paul R Cieslak.   

Abstract

This report summarizes new recommendation and updates previous recommendations of the Advisory Committee on Immunization Practices (ACIP) for postexposure prophylaxis (PEP) to prevent human rabies (CDC. Human rabies prevention---United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR 2008;57[No. RR-3]). Previously, ACIP recommended a 5-dose rabies vaccination regimen with human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV). These new recommendations reduce the number of vaccine doses to four. The reduction in doses recommended for PEP was based in part on evidence from rabies virus pathogenesis data, experimental animal work, clinical studies, and epidemiologic surveillance. These studies indicated that 4 vaccine doses in combination with rabies immune globulin (RIG) elicited adequate immune responses and that a fifth dose of vaccine did not contribute to more favorable outcomes. For persons previously unvaccinated with rabies vaccine, the reduced regimen of 4 1-mL doses of HDCV or PCECV should be administered intramuscularly. The first dose of the 4-dose course should be administered as soon as possible after exposure (day 0). Additional doses then should be administered on days 3, 7, and 14 after the first vaccination. ACIP recommendations for the use of RIG remain unchanged. For persons who previously received a complete vaccination series (pre- or postexposure prophylaxis) with a cell-culture vaccine or who previously had a documented adequate rabies virus-neutralizing antibody titer following vaccination with noncell-culture vaccine, the recommendation for a 2-dose PEP vaccination series has not changed. Similarly, the number of doses recommended for persons with altered immunocompetence has not changed; for such persons, PEP should continue to comprise a 5-dose vaccination regimen with 1 dose of RIG. Recommendations for pre-exposure prophylaxis also remain unchanged, with 3 doses of vaccine administered on days 0, 7, and 21 or 28. Prompt rabies PEP combining wound care, infiltration of RIG into and around the wound, and multiple doses of rabies cell-culture vaccine continue to be highly effective in preventing human rabies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20300058

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  95 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  [Traveling with immunosuppression].

Authors:  G Birkenfeld
Journal:  Internist (Berl)       Date:  2014-03       Impact factor: 0.743

3.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.

Authors:  RongCheng Li; YanPing Li; ShuQing Wen; HuiChun Wen; Yi Nong; Zhaojun Mo; Fang Xie; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.

Authors:  Nianmin Shi; Yibin Zhang; Huizhen Zheng; Zhenggang Zhu; Dingming Wang; Sihai Li; Yuhua Li; Liqing Yang; Junnan Zhang; Yunhua Bai; Qiang Lu; Zheng Zhang; Fengji Luo; Chun Yu; Li Li
Journal:  Hum Vaccin Immunother       Date:  2017-01-25       Impact factor: 3.452

6.  Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells.

Authors:  Ling Zhao; Harufusa Toriumi; Hualei Wang; Yi Kuang; Xiaofeng Guo; Kinjiro Morimoto; Zhen F Fu
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 7.  Prospects for dengue vaccines for travelers.

Authors:  Sl-Ki Lim; Yong Seok Lee; Suk Namkung; Jacqueline K Lim; In-Kyu Yoon
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

8.  Human Rabies Postexposure Prophylaxis Knowledge and Retention Among Health Professionals by Using an Online Continuing Education Module: Arizona, 2012 to 2015.

Authors:  Heather Venkat; James Matthews; Jigna Narang; Rebecca Sunenshine; Laura E Adams; Andrean M Bunko; Jessica R White; Craig Levy; Tammy Sylvester
Journal:  Pedagogy Health Promot       Date:  2018-04-06

9.  Clinical management and humoral immune responses to rabies post-exposure prophylaxis among three patients who received solid organs from a donor with rabies.

Authors:  N M Vora; L A Orciari; M Niezgoda; G Selvaggi; V Stosor; G M Lyon; R M Wallace; J Gabel; D R Stanek; P Jenkins; M Shiferaw; P Yager; F Jackson; C A Hanlon; I Damon; J D Blanton; S Recuenco; R Franka
Journal:  Transpl Infect Dis       Date:  2015-05-19       Impact factor: 2.228

10.  Community survey of rabies knowledge and exposure to bats in homes - Sumter County, South Carolina, USA.

Authors:  E W Lankau; S W Cox; S C Ferguson; J D Blanton; D M Tack; B W Petersen; C E Rupprecht
Journal:  Zoonoses Public Health       Date:  2014-05-10       Impact factor: 2.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.